Progress of erythropoientin in neonatal-related diseases.
- Author:
Lu-Lu LI
1
;
Hong WEI
Author Information
1. Department of Neonatology, Children's Hospital, Chongqing Medical University, Chongqing 400014, China.
- Publication Type:Journal Article
- MeSH:
Enterocolitis, Necrotizing;
drug therapy;
Erythropoietin;
chemistry;
therapeutic use;
Humans;
Hypoxia-Ischemia, Brain;
drug therapy;
Infant, Newborn;
Infant, Newborn, Diseases;
drug therapy;
Recombinant Proteins;
therapeutic use;
Retinopathy of Prematurity;
drug therapy
- From:
Chinese Journal of Contemporary Pediatrics
2011;13(12):1007-1010
- CountryChina
- Language:Chinese
-
Abstract:
Erythropoientin (Epo), a glycoprotein hormone, plays an important role in erythropoiesis and neuroprotection. Recently,Epo is also considered to have protective effects against hyperoxic lung injury, retinopathy of prematurity and neonatal necrotizing enterocolitis. Recombinant human erythropietin (rhEpo) as Epo gene cloning drug has been widely used in neonatal clinical practice.
